Central Trust Company’s Novo Nordisk NVO Stock Holding History

Central Trust Company’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$201K	Sell	4,201 -143	-3%	-$6.14K	﹤0.01%	619
2026 Q1	$160K	Sell	4,344 -63	-1%	-$2.98K	﹤0.01%	636
2025 Q4	$224K	Sell	4,407 -200	-4%	-$10.2K	﹤0.01%	560
2025 Q3	$256K	Sell	4,607 -438	-9%	-$25.6K	0.01%	544
2025 Q2	$348K	Sell	5,045 -975	-16%	-$66.3K	0.01%	471
2025 Q1	$418K	Hold	6,020	–	–	0.01%	434
2024 Q4	$518K	Buy	6,020 +81	+1%	+$8.76K	0.01%	407
2024 Q3	$707K	Buy	5,939 +41	+0.7%	+$5.47K	0.02%	368
2024 Q2	$842K	Hold	5,898	–	–	0.02%	342
2024 Q1	$757K	Sell	5,898 -72	-1%	-$8.57K	0.02%	359
2023 Q4	$618K	Sell	5,970 -34	-0.6%	-$3.36K	0.02%	377
2023 Q3	$546K	Buy	6,004 +328	+6%	+$28.9K	0.02%	392
2023 Q2	$459K	Buy	5,676 +1,138	+25%	+$93K	0.01%	426
2023 Q1	$361K	Buy	4,538 +8	+0.2%	+$567	0.01%	453
2022 Q4	$307K	Buy	4,530 +30	+0.7%	+$1.76K	0.01%	462
2022 Q3	$224K	Hold	4,500	–	–	0.01%	505
2022 Q2	$250K	Hold	4,500	–	–	0.01%	485
2022 Q1	$250K	Hold	4,500	–	–	0.01%	530
2021 Q4	$252K	Hold	4,500	–	–	0.01%	545
2021 Q3	$216K	Buy	4,500 +32	+0.7%	+$1.55K	0.01%	536
2021 Q2	$187K	Buy	4,468 +600	+16%	+$23.3K	0.01%	536
2021 Q1	$130K	Hold	3,868	–	–	0.01%	565
2020 Q4	$135K	Buy	3,868 +3,158	+445%	+$109K	0.01%	537
2020 Q3	$25K	Hold	710	–	–	﹤0.01%	735
2020 Q2	$23K	Hold	710	–	–	﹤0.01%	722
2020 Q1	$21K	Sell	710 -100	-12%	-$2.98K	﹤0.01%	757
2019 Q4	$23K	Hold	810	–	–	﹤0.01%	804
2019 Q3	$21K	Hold	810	–	–	﹤0.01%	786
2019 Q2	$20K	Buy	810 +100	+14%	+$2.47K	﹤0.01%	801
2019 Q1	$18K	Hold	710	–	–	﹤0.01%	787
2018 Q4	$16K	Sell	710 -1,326	-65%	-$29.5K	﹤0.01%	806
2018 Q3	$48K	Sell	2,036 -24	-1%	-$586	﹤0.01%	692
2018 Q2	$47K	Hold	2,060	–	–	﹤0.01%	681
2018 Q1	$51K	Sell	2,060 -1,120	-35%	-$29.4K	﹤0.01%	682
2017 Q4	$85K	Sell	3,180 -70	-2%	-$1.78K	0.01%	617
2017 Q3	$78K	Buy	3,250 +636	+24%	+$14.4K	0.01%	612
2017 Q2	$56K	Sell	2,614 -4,398	-63%	-$88.7K	﹤0.01%	669
2017 Q1	$120K	Sell	7,012 -2	-0%	-$35	0.01%	533
2016 Q4	$126K	Sell	7,014 -1,030	-13%	-$18.7K	0.01%	524
2016 Q3	$167K	Sell	8,044 -58	-0.7%	-$1.44K	0.01%	468
2016 Q2	$218K	Buy	8,102 +288	+4%	+$7.9K	0.02%	423
2016 Q1	$211K	Buy	7,814 +1,574	+25%	+$42.2K	0.02%	421
2015 Q4	$181K	Buy	6,240 +2,032	+48%	+$56.2K	0.01%	443
2015 Q3	$114K	Sell	4,208 -52	-1%	-$1.47K	0.01%	495
2015 Q2	$116K	Buy	4,260 +508	+14%	+$14.3K	0.01%	520
2015 Q1	$100K	Sell	3,752 -2	-0.1%	-$46	0.01%	528
2014 Q4	$80K	Sell	3,754 -12	-0.3%	-$268	0.01%	563
2014 Q3	$89K	Buy	3,766 +20	+0.5%	+$460	0.01%	552
2014 Q2	$86K	Buy	3,746 +460	+14%	+$10.2K	0.01%	559
2014 Q1	$75K	Sell	3,286 -1,034	-24%	-$22K	0.01%	576
2013 Q4	$80K	Hold	4,320	–	–	0.01%	563
2013 Q3	$73K	Hold	4,320	–	–	0.01%	565
2013 Q2	$67K	Buy	+4,320	New	+$71.9K	0.01%	539

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Central Trust Company's NVO Position: Q2 2026 in Review

Central Trust Company reduced its Novo Nordisk (NVO) stake by 3.3% in Q2 2026, selling an estimated $6.14K and leaving 4,201 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #619.

Central Trust Company first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $842K in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Central Trust Company held 4,201 shares of Novo Nordisk worth $201K as of Q2 2026.
Central Trust Company sold 143 Novo Nordisk shares in Q2 2026, an estimated $6.14K.
Novo Nordisk made up ﹤0.01% of Central Trust Company's portfolio in Q2 2026, its #619 holding.
Central Trust Company first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Central Trust Company's Novo Nordisk position peaked at $842K in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Central Trust Company's 13F filing for Q2 2026, filed 31 Jul 2026.